What's the most recent regulatory action in Streptococcus pyogenes infection?

Most recent: Cleocin T — FDA approved.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/streptococcus-pyogenes-infection.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Streptococcus pyogenes infection — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Streptococcus pyogenes infection (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Streptococcus pyogenes infection, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Teflaro	CEFTAROLINE FOSAMIL	AbbVie	Cephalosporin Antibacterial		2010-01-01
Ketek	TELITHROMYCIN	Sanofi	Ketolide Antibacterial	Potassium voltage-gated channel subfamily H member 2	2004-01-01
Cefditoren Pivoxyl	CEFDITOREN PIVOXIL	Vansen Pharma	Cephalosporin Antibacterial		2001-01-01
Zyvox	linezolid	Pfizer	Oxazolidinone Antibacterial [EPC]	Amine oxidase [flavin-containing] A	2000-01-01
Avelox	moxifloxacin	Bayer AG	Fluoroquinolone antibiotic (fourth-generation)	DNA gyrase, DNA gyrase subunit A, DNA topoisomerase 4 subunit A	1999-12-10
Levaquin	levofloxacin	Generic (originally Daiichi Sankyo/J&J)	Fluoroquinolone Antibacterial [EPC]	CAAX prenyl protease 2, Multidrug and toxin extrusion protein 1, Potassium voltage-gated channel subfamily H member 2	1996-12-20
Maxipime	CEFEPIME	Baxter	Cephalosporin Antibacterial		1996-01-01
Maxipime	Cefepime Hydrochloride	Baxter	Cephalosporin	Bacterial cell wall peptidoglycan	1996-01-01
Cedax	ceftibuten	Burke Therap	Cephalosporin Antibacterial		1995-01-01
Zithromax	azithromycin	Pfizer Inc.	Macrolide antibiotic (azalide)	Canalicular multispecific organic anion transporter 1, Taste receptor type 2 member 4, Motilin receptor	1991-11-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

2026-03-23 — Cleocin T · FDA · approved · US
2026-03-18 — Cleocin T · FDA · approved · US

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 15 drugs in Streptococcus pyogenes infection
Pfizer · 5 drugs in Streptococcus pyogenes infection
GSK · 2 drugs in Streptococcus pyogenes infection
Bayer AG · 2 drugs in Streptococcus pyogenes infection
Pai Holdings Pharm · 2 drugs in Streptococcus pyogenes infection
Baxter · 2 drugs in Streptococcus pyogenes infection
Bristol-Myers Squibb · 2 drugs in Streptococcus pyogenes infection
Burke Therap · 1 drug in Streptococcus pyogenes infection
Generic (originally Beecham/GSK) · 1 drug in Streptococcus pyogenes infection
Assistance Publique - Hôpitaux de Paris · 1 drug in Streptococcus pyogenes infection
Generic (originally Abbott/Lilly) · 1 drug in Streptococcus pyogenes infection
Generic (originally Abbott/AbbVie) · 1 drug in Streptococcus pyogenes infection

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Streptococcus pyogenes infection:

Cite this brief

Drug Landscape (2026). Streptococcus pyogenes infection — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/streptococcus-pyogenes-infection. Accessed 2026-06-10.

Streptococcus pyogenes infection full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing